Topotecan in the treatment of ovarian cancer

摘要: Epithelial ovarian cancer is the eighth most common and fifth cause of cancer-related death in women USA. While with Stage III/IV disease respond to first-line therapy a platinum/taxane combination, only 10–30% are long-term survivors. Topotecan, topoisomerase I inhibitor, approved by US FDA for treatment relapsed at dose schedule 1.5 mg/m2/day 5 days every 21 days. This causes significant, noncumulative myelosuppression, various alternate regimens have been explored. A randomized Phase II Gynecological Oncology Group trial currently investigating weekly topotecan versus five-times daily schedule. Multiple trials evaluated incorporation front-line cancer, although none demonstrated benefit this approach.